clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Faghih R et al. Synthesis and antibacterial activity of (9S)-9-dihydroclarithromycin. 1990 J. Antibiot. pmid:2147921
Perronne C et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. 1990 Antimicrob. Agents Chemother. pmid:2171421
Morimoto S et al. Chemical modification of erythromycins. III. In vitro and in vivo antibacterial activities of new semisynthetic 6-O-methylerythromycins A, TE-031 (clarithromycin) and TE-032. 1990 J. Antibiot. pmid:2139023
Kohno Y et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. 1990 Antimicrob. Agents Chemother. pmid:2140497
Marchi E Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. 1990 Curr Med Res Opin pmid:2140546
Scaglione F Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. 1990 Curr Med Res Opin pmid:2140547
Morimoto S et al. Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A. 1990 J. Antibiot. pmid:2141599
Hardy DJ et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. 1990 Antimicrob. Agents Chemother. pmid:2143642
Cacciapuoti AF et al. Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives. 1990 J. Antibiot. pmid:2145254
Adachi T et al. Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A. 1989 J. Antibiot. pmid:2737946
Gorzynski EA et al. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. 1989 Antimicrob. Agents Chemother. pmid:2524998
Fernandes PB et al. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. 1989 Antimicrob. Agents Chemother. pmid:2523688
Fernandes PB et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. 1989 Antimicrob. Agents Chemother. pmid:2530933
Kohno Y et al. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. 1989 Antimicrob. Agents Chemother. pmid:2526615
Tinel M et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. 1989 J. Pharmacol. Exp. Ther. pmid:2527301
Adachi T et al. Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by Mucor circinelloides. 1989 J. Antibiot. pmid:2529234
Naik S and Ruck R In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. 1989 Antimicrob. Agents Chemother. pmid:2817858
Sasaki J et al. Microbial transformation of 6-O-methylerythromycin derivatives. 1988 J. Antibiot. pmid:2971032
Adachi T et al. 14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. 1988 J. Antibiot. pmid:2971033
Waites KB et al. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. 1988 Antimicrob. Agents Chemother. pmid:2973283
Barry AL et al. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. 1988 J. Clin. Microbiol. pmid:2976773
Chang HR and Pechère JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2837140
Barry AL et al. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. 1988 Antimicrob. Agents Chemother. pmid:2840016
Segreti J et al. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2952061
Benson CA et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2952063
Barry AL et al. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. 1987 Antimicrob. Agents Chemother. pmid:2952064
Chin NX et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. 1987 Antimicrob. Agents Chemother. pmid:2953303
Bowie WR et al. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2953304
Hanson CW et al. Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). 1987 J. Clin. Microbiol. pmid:2954995
Floyd-Reising S et al. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. 1987 Antimicrob. Agents Chemother. pmid:2955742
Fernandes PB et al. Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. 1987 Antimicrob. Agents Chemother. pmid:2957954
Fernandes PB et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. 1986 Antimicrob. Agents Chemother. pmid:2949695
Morimoto S et al. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. 1984 J. Antibiot. pmid:6706855
Pike VW et al. Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate. 1984 Int J Appl Radiat Isot pmid:6231252
Zullo A et al. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol pmid:22249086
Monego F et al. Molecular identification and typing of Mycobacterium massiliense isolated from postsurgical infections in Brazil. Braz J Infect Dis pmid:22230849
Siemens J et al. Transport of pharmaceuticals in columns of a wastewater-irrigated Mexican clay soil. J. Environ. Qual. pmid:20830907
Ubhayawardana NL et al. Detection of clarithromycin-resistant Helicobacter pylori strains in a dyspeptic patient population in Sri Lanka by polymerase chain reaction-restriction fragment length polymorphism. Indian J Med Microbiol pmid:26068338
Baylor P and Larson R Mycobacterium avium septicemia with ARDS in a patient with diabetes mellitus and no other known immune-compromising condition. J Intensive Care Med pmid:19188269
Colomina Rodríguez J et al. [Impact of Integrated Model for Rational Use of Antibiotics in a health area (project MIURA)]. Rev. Esp. Salud Publica pmid:20661527
Lage R et al. Mycobacterium chelonae cutaneous infection in a patient with mixed connective tissue disease. An Bras Dermatol pmid:25672306
Mishra A et al. A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin. Indian J Pharmacol pmid:25298587
Liang CM et al. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J pmid:25163495
Wang J et al. Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study. Saudi J Gastroenterol pmid:26655129
Moreira C et al. Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. An Bras Dermatol pmid:28954125
Dajani A et al. Importance of Helicobacter pylori eradcation for maintenance of remission of drug associated peptic ulcer disease. Saudi J Gastroenterol pmid:19858579
Doorakkers E et al. Helicobacter pylori eradication in the Swedish population. Scand. J. Gastroenterol. pmid:28323552
Yamazhan T et al. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract pmid:16220015
Pachot JI et al. Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci pmid:12753725
Radzikowska E et al. Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia. Adv Clin Exp Med pmid:28028949